Success examples
Canonical BAF complex activity shapes the enhancer landscape that licenses CD8+ T cell effector and memory fates

McDonald B., Chick B. Y., Ahmed N. S., Burns M., Ma S., Casillas E., Chen D., Mann T. H., O'Connor C., Hah N., Hargreaves D. C., Kaech S. M.

Immunity 2023, 56(6):1303-1319.e5.

SMARCA2/4 PROTAC
DOI
PubMed
Success examples
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Kim D., Herdeis L., Rudolph D., Zhao Y., Böttcher J., Vides A., Ayala-Santos C. I., Pourfarjam Y., Cuevas-Navarro A., Xue J. Y., Mantoulidis A., Bröker J., Wunberg T., Schaaf O., Popow J., Wolkerstorfer B., Kropatsch K. G., Qu R., de Stanchina E., Sang B., Li C., McConnell D. B., Kraut N., Lito P.

Nature 2023, 619(7968):160-166.

KRAS switch I/II pocket inhibitor
DOI
PubMed
General literature
Open resources for chemical probes and their implications for future drug discovery

Balıkçı E., Marques A. M. C., Hansen J. S., Huber K. V. M.

Expert Opin Drug Discov. 2023, 18(5):505-513. open access

DOI
PubMed
Success examples
AMPK activation protects against prostate cancer by inducing a catabolic cellular state

Penfold L., Woods A., Pollard A. E., Arizanova J., Pascual-Navarro E., Muckett P. J., Dore M. H., Montoya A., Whilding C., Fets L., Mokochinski J., Constantin T. A., Varela-Carver A., Leach D. A., Bevan C. L., Nikitin A. Y., Hall Z., Carling D.

Cell Rep. 2023, 42(4):112396.

AMPK Activator
DOI
PubMed
Success examples
Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors

Malone C. F., Kim M., Alexe G., Engel K., Forman A. B., Robichaud A., Saur Conway A., Goodale A., Meyer A., Khalid D., Thayakumar A., Hatcher J. M., Gray N. S., Piccioni F., Stegmaier K.

Cancer Res 2023, 83(2):285-300.

CDK8 inhibitor
DOI
PubMed
General literature
The era of high-quality chemical probes

Licciardello M. P., Workman P.

Med Chem. 2022, 13(12):1446-1459. open access

DOI
PubMed